Pfizer gets full US regulatory approval for cervical cancer drug
HQ Team April 30, 2024: The US health regulator has approved Pfizer’s drug to treat cervical cancer patients whose disease has progressed beyond.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 30, 2024: The US health regulator has approved Pfizer’s drug to treat cervical cancer patients whose disease has progressed beyond.
HQ Team December 13, 2023: Pfizer is expected to close the $43 billion acquisition of Seagen by Thursday as the company announced restructuring.
HQ Team May 18, 2023: Pfizer plans to raise long-term debt worth $31 billion to finance its acquisition of Seagen, according to a.